Bridging Interventional Development Gaps (BrIDGs) provides eligible scientists with no-cost access to contractor services, such as toxicology studies, for pre-clinical therapeutic development. BrIDGs is now housed in the National Center for Advancing Translational Sciences (NCATS).
Visit: http://www.ncats.nih.gov/research/rare-diseases/bridgs/bridgs.html for more information.
Stories of BrIDGs Success
Brief descriptions of two researchers who successfully made use of BrIDGs services are available on pages 39 & 40 of the commemorative book: A Decade of Discovery: The NIH Roadmap and Common Fund. In these descriptions, you'll learn about the BrIDGs program's contributions to a new therapeutic candidate for Beta Thalassemia and a novel gene therapy approach to Pakinson's disease. Click on the image to get started.
Schematic for BrIDGs concept: Where private sector capacity for drug development is limited or not available, the NIH can help to bridge the gap by providing resources needed to facilitate development of promising therapies